Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Biosimilars
Eager to create an ecosystem for innovation, a draft policy document prepared by India's Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers has proposed to cut down the time taken for regulatory approvals for innovative products by at least 50% within the next two years. The policy aims to catalyze R&D in the pharma and medtech sector, and to propel India to become a leader in drug discovery through incubating an entrepreneurial environment, reports The Pharma Letter’s India correspondent. 10 November 2021
Pharmaceutical
The COVID-19 pandemic generated multiple challenges for the Latin American pharmaceutical industry, especially in matters of codes of ethics and crisis management. 8 November 2021
Pharmaceutical
Russia is increasing exports of its anti-COVID-19 vaccines this year, with the biggest markets being Argentina, Kazakhstan and India, reports The Pharma Letter’s local correspondent. 8 November 2021
Pharmaceutical
The National Institute for Health and Care Excellence's (NICE) consultation on the proposed changes to its methods and processes of health technology assessment closed on October 13. Here Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, provides an Expert View on the proposed fresh approach to health technology assessment and how this will allow continued fair and fast access to medicines in the National Health Service (NHS). 5 November 2021
Pharmaceutical
The value of influenza vaccines purchases in Russia in January-September of the current year increased by almost 25%, to 14.5 billion roubles ($211 million), according to recent statements by the Russian Ministry of Health and some local media, reports The Pharma Letter’s local correspondent. 2 November 2021
Pharmaceutical
An estimated 2,500,000 people in the world have multiple sclerosis (MS), a condition which can cause a broad range of symptoms and affect multiple parts of the body. 1 November 2021
Generics
Seeking to strengthen India’s position globally in terms of pharmaceuticals, India has reached out to top American pharmaceutical companies seeking investment in the country's pharma and medical devices sector. With investments of about $5 billion in Indian companies, American private investment firm Bain Capital says it is looking forward to investing 'even more' in India, post government officials wooing investors, reports The Pharma Letter’s India correspondent. 28 October 2021
Pharmaceutical
For Gaucher Disease Awareness Month, October, we take a look at advances in the pharmacological treatment of this rare condition. 28 October 2021
Pharmaceutical
In October 2016, Gabriel Baertschi left his role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 27 October 2021
Pharmaceutical
Paul Domenet, partner and communications creative director at Free The Birds, offers an Expert View on how big pharma can improve its image. 26 October 2021
Pharmaceutical
The news cycle has hit overdrive in the UK ahead of a frenetic couple of weeks that include the Autumn Budget, a Comprehensive Spending Review and the COP26 conference in Glasgow. 26 October 2021
Pharmaceutical
The All-Russian Union of Patients (ARUP), one of Russia’s leading associations, representing the interests of patients in Russia, has appealed to the national government and the State Duma to increase expenditures on the provision of domestic patients with drugs for the treatment of cardiovascular diseases, reports The Pharma Letter’s local correspondent. 26 October 2021
Generics
Nativa, a well-known Russian producer of generics, is challenging the recent cancellation of its patent for its anticancer drug sunitinib in the intellectual property court in Russia, according to some local media, reports The Pharma Letter’s local correspondent. 25 October 2021
Biotechnology
As the pandemic broke, UK pharma major AstraZeneca had the wind in its sales, with a rising stock price and a winning R&D formula. 25 October 2021
Biosimilars
A slew of regulatory reforms is in the offing for the biotech industry in India, with the government seeking to accelerate biologics and biosimilar development in the country. Apart from an amendment to Guidelines on Similar Biologics, the industry is to get the benefit of certain measures that will facilitate commercial stockpiling of biosimilar products before issuance of marketing authorization in order to propel their launch in the market in line with the US Food and Drug Administration, reports The Pharma Letter’s India correspondent. 19 October 2021
Pharmaceutical
The Russian government has officially presented a new state program for the development of the domestic pharmaceutical industry for the next 10 years - "Pharma-2030," reports The Pharma Letter’s local correspondent. 19 October 2021
Pharmaceutical
China’s Center for Drug Evaluation (CDE), a division under the Chinese drug industry watchdog the National Medical Products Administration (NMPA), has been churning out guidelines in the past year to help the nation transform from a generics/biosimilar maker into a novel drug development hub, reports The Pharma Letter’s local correspondent. 18 October 2021
Biotechnology
One of the latest developments in medicine is the advent of cell and gene therapies (CGTs). Cell therapies include cellular immunotherapies, cancer vaccines, and stem cells. Gene therapies are designed to modify the expression of specific genes or alter the biological properties of cells for the treatment of diseases. 18 October 2021
Pharmaceutical
An Expert View from Gary Connors, partner at Oliver Wight, on intellectual property rights protection and drug development. 15 October 2021
Pharmaceutical
Since Donald Trump’s 2018 “American Patients First” plan, and long before, drug pricing in the USA has been both a lightning rod for strong opinions and stubbornly resistant to reform. 12 October 2021
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze